Is GBRRF or JNJ a better dividend investment in 2026?

GBRRF currently yields 2173.91% with a 5% 5-year dividend growth rate. JNJ yields 2.13% with 5.8% growth. The better choice depends on your goal: GBRRF offers higher current income.

What is the dividend yield difference between GBRRF and JNJ?

GBRRF has a forward dividend yield of 2173.91% ($2.00/share annually). JNJ yields 2.13% ($5.20/share annually). The yield gap is 2171.78 percentage points.

Home › Compare › GBRRF vs JNJ

GBRRF vs JNJ: Dividend Comparison 2026

GBRRF yields 2173.91% · JNJ yields 2.13%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 GBRRF wins by $21654764992.52M in total portfolio value

INVESTMENT

TIME HORIZON10 years

GBRRF

● Live price

2173.91%

Share price

$0.09

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$21654764992.55M

Annual income

$19,857,848,853,590,590.00

Full GBRRF calculator →

JNJ

Johnson & Johnson

● Live price

2.13%

Share price

$244.44

Annual div

$5.20

5Y div CAGR

28%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$30.3K

Annual income

$4,689.40

Full JNJ calculator →

Portfolio growth — GBRRF vs JNJ

📍 GBRRF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	GBRRF	JNJ
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, GBRRF + JNJ cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

GBRRF pays

JNJ pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GBRRF

Annual income on $10K today (after 15% tax)

$184,782.61/yr

After 10yr DRIP, annual income (after tax)

$16,879,171,525,552,002.00/yr

JNJ

Annual income on $10K today (after 15% tax)

$180.82/yr

After 10yr DRIP, annual income (after tax)

$3,985.99/yr

At 15% tax rate, GBRRF beats the other by $16,879,171,525,548,016.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GBRRF + JNJ for your $10,000?

GBRRF: 50%JNJ: 50%

100% JNJ50/50100% GBRRF

Portfolio after 10yr

$10827382496.29M

Annual income

$9,928,924,426,797,640.00/yr

Blended yield

91.70%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

GBRRF

No analyst data

Altman Z

-857.0

Piotroski

2/9

JNJ

Analyst Ratings

Buy

Hold

Sell

Consensus: Buy

Price Target

$228.73

-6.4% upside vs current

Range: $190.00 — $265.00

Altman Z

5.2

Piotroski

4/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GBRRF buys

JNJ buys

No recent congressional trades found for GBRRF or JNJ in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricGBRRFJNJ

Forward yield	2173.91% ✓	2.13%
Annual dividend / share	$2.00	$5.20 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	28% ✓
Portfolio after 10y	$21654764992.55M ✓	$30.3K
Annual income after 10y	$19,857,848,853,590,590.00 ✓	$4,689.40
Total dividends collected	$21528016497.42M ✓	$15.4K
Payment frequency	quarterly	quarterly
Sector	Stock	Healthcare

Year-by-year: GBRRF vs JNJ ($10,000, DRIP)

Year	GBRRF Portfolio	GBRRF Income/yr	JNJ Portfolio	JNJ Income/yr	Gap
1← crossover	$228,091	$217,391.30	$10,592	$272.30	+$217.5K → GBRRF
2	$4,878,176	$4,634,118.33	$11,289	$357.73	+$4.87M → GBRRF
3	$97,845,472	$92,625,823.19	$12,123	$472.89	+$97.83M → GBRRF
4	$1,841,021,843	$1,736,327,188.73	$13,141	$629.86	+$1841.01M → GBRRF
5	$32,502,648,796	$30,532,755,424.15	$14,408	$846.81	+$32502.63M → GBRRF
6	$538,559,125,266	$503,781,291,054.08	$16,021	$1,151.60	+$538559.11M → GBRRF
7	$8,377,664,463,744	$7,801,406,199,709.04	$18,122	$1,588.22	+$8377664.45M → GBRRF
8	$122,381,239,723,864	$113,417,138,747,658.05	$20,930	$2,228.20	+$122381239.70M → GBRRF
9	$1,679,360,877,531,610	$1,548,412,951,027,075.00	$24,792	$3,191.91	+$1679360877.51M → GBRRF
10	$21,654,764,992,549,412	$19,857,848,853,590,590.00	$30,274	$4,689.40	+$21654764992.52M → GBRRF

GBRRF vs JNJ: Complete Analysis 2026

GBRRF — Stock

Gabriel Resources Ltd. engages in the exploration, evaluation, and development of precious metal mining properties in Romania. The company primarily explores for gold, silver, and copper deposits. It primarily holds interest in the Bucium exploration concession covering an area of 2,325 hectares located in Western Transylvania. The company was formerly known as Starx Resource Corp. and changed its name to Gabriel Resources Ltd. in April 1997. Gabriel Resources Ltd. was incorporated in 1986 and is based in Whitehorse, Canada.

Full GBRRF Calculator →

JNJ — Healthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →

📬

Get this GBRRF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GBRRF vs SCHD GBRRF vs JEPI GBRRF vs O GBRRF vs KO GBRRF vs MAIN GBRRF vs ABBV GBRRF vs MRK GBRRF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.